Introduction {#s1}
============

Systemic juvenile idiopathic arthritis (sJIA) and adult-onset Still disease (AOSD) represent two multifactorial nonhereditary autoinflammatory disorders related to pediatric and adult patients, respectively, characterized by a defective control of innate immunity, as depicted for hereditary autoinflammatory disorders, and by daily high spiking fevers along with systemic features including serositis, evanescent rash, generalized lymphoadenopathy, and arthritis ([@B2]; [@B4]; [@B40]; [@B7]; [@B22]). These two conditions are accompanied by a relevant risk of mortality ([@B38]; [@B17]; [@B27]; [@B18]; [@B7]), making a timely diagnosis as well as a prompt treatment mandatory. Treatment of both sJIA and AOSD has traditionally relied on nonsteroidal anti-inflammatory drugs, corticosteroids (CS), and conventional disease-modifying antirheumatic drugs (cDMARDs), with methotrexate being the most frequently used ([@B6]; [@B18]). However, there is limited evidence, especially for sJIA, regarding other effective drugs, such as cyclosporine, thalidomide, and other novel agents ([@B18]; [@B24]). The lack of standardized therapeutic guidelines represents an important unmet need, and management of both sJIA and AOSD still remains empirical. Biotechnological drugs have also proved to be effective in AOSD ([@B45]), and indeed many compelling pathogenetic data ([@B36]; [@B3]; [@B26]; [@B6]) consider interleukin (IL)-1 as the main orchestrating cytokine in sJIA and AOSD pathways, providing the biologic rationale of IL-1 inhibition in these two entities, which are now deemed *autoinflammatory* in nature ([@B10]; [@B42]).

Anakinra (ANA) is a recombinant human IL-1 receptor "antagonist," which binds tightly to the IL-1 receptor and competitively prevents activation of this receptor by either IL-1α and IL-1β ([@B28]). After showing its paramount efficacy in the cryopyrin-associated periodic syndrome, a rare IL-1-mediated hereditary autoinflammatory disorder ([@B1]; [@B41]), ANA started to be employed also in AOSD and sJIA. From its first use on AOSD ([@B43]) and sJIA ([@B50]), a growing body of evidence has reported the considerable clinical efficacy of ANA in both entities ([@B39]; [@B33]; [@B47]; [@B5]) with several studies suggesting this targeted biologic therapy as first- or early second-line treatment ([@B36]; [@B29]; [@B30]; [@B12]; [@B49]; [@B35]). Nevertheless, only a few data are available in regard to long-term efficacy and tolerability of ANA in sJIA and AOSD ([@B20]; [@B19]; [@B8]; [@B34]; [@B5]).

Herein, we report a multicenter real-life experience on patients with sJIA and AOSD in the long term, evaluating ANA effectiveness in terms of drug retention rate (DRR) along with predictive factors associated with treatment withdrawal.

Patients and Methods {#s2}
====================

Study Design and Participants {#s2_1}
-----------------------------

Medical records of 61 patients affected by sJIA and 76 patients affected by AOSD, all treated with ANA and enrolled from January 2008 until July 2016 in 25 Italian tertiary rheumatology referral centers, were retrospectively reviewed. Clinical and therapeutic data were collected in combination with general and demographic data, such as age, gender, age at disease onset, disease duration, treatment delay, the anti-IL-1 agent employed, dosages used, concomitant and previous treatments, and overall anti-IL-1 treatment duration.

sJIA was diagnosed according to the revised International League of Association for Rheumatology (ILAR) criteria ([@B37]), while AOSD diagnosis was established according to the Yamaguchi criteria ([@B52]). In accordance with the best standards of care, all patients were systematically followed-up every 3 months and/or in case of necessity (disease flare and/or safety issues). Before starting anti-IL-1 treatment with ANA, patients underwent a complete medical examination and an extensive work-up for infectious diseases, including search for markers of hepatitis B and C viruses, urine culture, QuantiFERON test, and chest X-ray to rule out active or latent infections. ANA dosages ranged from 1 to 4 mg/kg/day for pediatric patients, while 100 mg/day was the starting dose for adult patients.

Aims and Endpoints {#s2_2}
------------------

Primary aim of the study was to examine the overall DRR of ANA in sJIA and AOSD patients. Secondary aims were to: (i) explore the influence of the biologic line of treatment and the concomitant use of cDMARDs on DRR in the whole sample and stratified according to the disease thereafter; (ii) find eventual predictive factors associated with events leading to drug discontinuation. The CS- and cDMARDS-sparing effects, impact of treatment delay on survival, and record of safety profile were considered ancillary aims of the study.

The primary endpoint was evaluated by the Kaplan--Meier survival curve at 12, 24, 48, and 60 months of follow-up. Secondary endpoints were as follows: (i) using limit estimators to compare survival curves of monotherapy *versus* combination therapy with cDMARDs and significant differences on survival curves, distinguishing between biologic-naïve patients and those already treated with other biologics; the analysis was then extended by stratifying limit estimators according to the disease; (ii) to evaluate whether demographic, clinical, and therapeutic variables could predict time-to-treatment discontinuation. Finally, ancillary aims were explored by the identification of potential statistically significant differences in the mean treatment delay, subdividing our sample in patients continuing and patients discontinuing treatment as well as on CS- and cDMARDs-sparing effect, and description of AEs.

Statistical Analysis {#s2_3}
--------------------

Data were analyzed using IBMSPSS Statistics for Windows, version 24 (IBM Corp., Armonk, NY, USA). Descriptive statistics was used to display mean and standard deviation (SD) or median and interquartile ranges (IQRs), as required. We analyzed data distribution with the Shapiro--Wilk test. Categorical variables were analyzed by McNemar test for repeated measures, while differences in means were investigated with Mann--Whitney *U* test. Time-to-event analysis was performed according to the Kaplan--Meier method, with the event being ANA discontinuation. Patients discontinuing ANA due to remission were not included in the statistical analysis. Survival curves were compared using both long-rank and Breslow test as limit estimators. Event-free survival was assessed with a Cox proportional hazard model, using 95% confidence interval (CI) for hazard ratio (HR) aiming to evaluate any relation of demographic, clinical, and therapeutic data with DRR. The threshold for statistical significance was set to *p* \< 0.05, and all *p* values were two-sided.

Results {#s3}
=======

We examined medical charts of 137 patients (56 males, 81 females) affected by sJIA (61 patients) and AOSD (76 patients), all receiving ANA within the study period lasting from January 2008 to July 2016.

Demographic, clinical, and therapeutic data of sJIA and AOSD are detailed in [**Tables 1**](#T1){ref-type="table"} and [**2**](#T2){ref-type="table"}, respectively. Female-to-male ratio was 1.03 for sJIA patients and 1.92 for the AOSD ones. The median ± IQR time of treatment duration was 18.00 ± 27.00 months. The mean ± SD age at disease onset for AOSD was 39.98 ± 15.05, while the median age ± IQR at disease onset for sJIA was 5.80 ± 7.10 years. Forty-two out of 137 patients were coadministered with cDMARDs, and 25 subjects had been previously treated with other biologic agents.

###### 

Demographic and therapeutic features of patients with sJIA.

  ----------------------------------------- --------------------------------------------------------------------------------------------
  Patients no.                              61
  Male/Female no.                           30/31
  Mean age ± SD (years)                     12.97 ± 7.05
  Age at onset (median ± IQR) (years)       5.80 ± 7.10
  Age at diagnosis (median ± IQR) (years)   6.70 ± 7.30
  Disease duration (median ± IQR) (years)   4.00 ± 5.93
  Treatment delay (median ± IQR) (years)    2.10 ± 6.64
  Previous biologics                        ETN (n = 9); IFX (n = 1); ADA (n = 1); TCZ (n = 2); CAN (n = 1); RTX (n = 1); ABA (n = 1).
  Previous cDMARDs                          MTX (n = 14); CsA (n = 13); SSZ (n = 2); LFN (n = 2); HCQ (n = 2)
  Concomitant cDMARDs                       MTX (n = 8); CsA (n = 8); SSZ (n = 1); LFN (n = 1); HCQ (n = 2)
  ----------------------------------------- --------------------------------------------------------------------------------------------

ABA, abatacept; ADA adalimumab; CAN, canakinumab; CsA cyclosporine; ETN, etanercept; HCQ, hydroxychloroquine; IFX, infliximab; LFN, leflunomide; MTX, methotrexate; RTX, rituximab; SSZ, sulfasalazine; TCZ, tocilizumab; sJIA, systemic juvenile idiopathic arthritis; IQR, interquratile range; cDMARDs, conventional disease modifying anti-rheumatic drugs.

###### 

Demographic and therapeutic data of patients with AOSD.

  ----------------------------------------- -------------------------------------------------------------------------------------------------------------------------
  Patients no.                              76
  Male/Female no.                           26/50
  Mean age ± SD (years)                     47.90 ± 15.13
  Age at onset (mean ± SD) (years)          39.98 ± 15.05
  Age at diagnosis (mean ± SD) (years)      41.96 ± 14.49
  Disease duration (median ± IQR) (years)   6.00 ± 9.00
  Treatment delay (median ± IQR) (years)    3.25 ± 7.47
  Previous biologics                        ETN (n = 9); IFX (n = 6); ADA (n = 3); GOL (n = 1); TCZ (n = 1); RTX (n = 1)
  Previous cDMARDs                          MTX (n = 42); CsA (n = 18); SSZ (n = 4); LFN (n = 2); HCQ (n = 19); AZA (n = 4); CPH (n = 1); CQN (n = 2); COL (n = 2).
  Concomitant cDMARDs                       MTX (n = 18); CsA (n = 4); SSZ (n = 1); LFN (n = 2); HCQ (n = 7)
  ----------------------------------------- -------------------------------------------------------------------------------------------------------------------------

ADA, adalimumab; AZA, azathioprine; CQN, chloroquine; COL, colchicine; CPH, cyclophosphamide; CsA, cyclosporine; ETN, etanercept; GOL, golimumab; HCQ, hydroxychloroquine; IFX, infliximab; LFN, leflunomide; MTX, methotrexate; RTX, rituximab; SSZ, sulfasalazine; TCZ, tocilizumab AOSD, Adult onset Still disease; IQR, interquartile range; cDMARDs, conventional disease modifying anti-rheumatic drugs.

The cumulative retention rate of ANA at 12, 24, 48, and 60 months of follow-up was 74.3%, 62.9%, 49.4%, and 49.4%, respectively ([**Figure 1A**](#f1){ref-type="fig"}), without any significant differences between sJIA and AOSD patients (*p* = 0.164) ([**Figure 1B**](#f1){ref-type="fig"}). Conversely, statistically significant differences were observed between biologic-naïve patients and those previously treated with other biologic drugs (*p* = 0.009) ([**Figure 2A**](#f2){ref-type="fig"}). The difference between the two subgroups persisted also after adjustment for pathology (*p* = 0.013). In addition, no statistically significant differences were detected between patients in monotherapy and the subgroup coadministered with cDMARDs (*p* = 0.473) ([**Figure 2B**](#f2){ref-type="fig"}). Cox regression analysis identified two variables associated with a higher hazard of treatment withdrawal: line of biologic treatment and AEs. More in detail, patients previously treated with other biologics displayed a higher HR \[HR = 1.818 (CI 1.007--3.282), *p* = 0.047\]. Similarly, the subgroup experiencing the occurrence of AEs was also associated with a higher hazard of treatment discontinuation \[HR = 3.029 (CI 1.750--5.242), *p* \< 0.0001\].

![Kaplan--Meier curves describing the cumulative survival of Anakinra related to: **(A)** the entire cohort of patients, **(B)** the log rank test comparing drug survival in systemic juvenile idiopathic arthritis and adult onset Still disease.](fphar-10-00918-g001){#f1}

![Kaplan--Meier curves comparing cumulative drug survival of Anakinra between biologic-naïve patients and those pretreated with other biologics **(A)**, between patients undergoing monotherapy and the subgroup coadministered with conventional disease modifying anti-rheumatic drugs **(B)**.](fphar-10-00918-g002){#f2}

Moreover, the median treatment delay was significantly higher among patients discontinuing ANA (4.00 ± 6.83 years) compared to the subgroup that was able to retain it (0.66 years ± 3.24) (*p* \< 0.0001). With regard to the CS-sparing effect, a significant reduction in the number of patients requiring the support of CS was found (*p* = 0.033). Fifteen patients were able to interrupt CS therapy. A significant cDMARDs-sparing effect was also observed (*p* \< 0.0001) and 35 patients were able to discontinue treatment with immunosuppressive drugs.

AEs occurred in 40 out of 137 patients (29.2%) (11 in sJIA and 29 in AOSD patients), with the most frequent being injection site reactions (n = 18), followed by generalized skin rashes (n = 10), flue-like syndrome (n = 2), thrombocytopenia (n = 2), transient mild respiratory problems (n = 1), and abnormal level of liver enzymes (n = 1). With regard to serious AEs, two cases of pneumonia along with lower limb ulcers (n = 1), myocarditis (n = 1), dilated cardiomyopathy (n = 1), and macrophage activation syndrome (MAS) (n = 1) were recorded. Death occurred in four patients experiencing serious AEs (two patients with pneumonia and the remaining two suffering from myocarditis and dilatative cardiomyopathy, respectively). Overall, AEs caused treatment discontinuation in 29 cases. The remaining causes for discontinuing treatment were as follows: clinical remission (n = 25), lack of efficacy (n = 8), loss of efficacy (n = 15), and pregnancy (n = 1). AEs are summarized in [**Table 3**](#T3){ref-type="table"}.

###### 

Adverse events recorded for sJIA and AOSD.

  sJIA                                 N
  ------------------------------------ ----
  Injections site reaction             7
  Generalized skin rash                2
  Hepatic toxicity                     1
  Transient and mild breath problems   1
  AOSD                                 N
  Injection site reaction              11
  Generalized skin rash                8
  Thrombocytopenia                     2
  Flu-like syndrome                    2
  Pneumonia                            2
  Lower limb ulcers                    1
  Myocarditis                          1
  Dilated cardiomyopathy               1
  macrophage activation syndrome       1

sJIA, systemic juvenile idiopathic arthritis; AOSD, Adult onset Still disease.

Discussion {#s4}
==========

sJIA is the pediatric counterpart of AOSD and both disorders represent hard-to-handle autoinflammatory conditions characterized by high mortality rate due to the risk of severe fatal complications ([@B17]; [@B27]; [@B21]; [@B18]; [@B44]; [@B7]). Additionally, a high percentage of patients with sJIA and AOSD can be refractory to CS, conventional immunosuppressants, and also several biologic agents ([@B33]; [@B34]; [@B9]; [@B14]). Nevertheless, in the current biologic era, novel targeted treatments have favorably resized the therapeutic armamentarium for these two entities. Several cytokines, such as IL-1 and IL-18, processed through the inflammasome machinery, and also IL-6 have been implicated in their pathogenesis. Particularly, since IL-1 was considered the master mediator of inflammatory pathway in both sJIA and AOSD ([@B36]; [@B3]; [@B26]; [@B6]), an increasing experience of IL-1 blockade has matured over time ([@B20]; [@B30]; [@B39]; [@B33]; [@B34]; [@B35]; [@B47]; [@B5]).

In the present study we have highlighted the real-life experience of 25 Italian tertiary referral centers with the recombinant human IL-1 receptor ANA in the treatment of sJIA and AOSD, focusing on long-term effectiveness as well as on any potential differences between the two disorders. The study involved 61 sJIA patients and 76 ASOD patients. In the sJIA subgroup males and females were equally represented, whereas AOSD sample was skewed toward females, who composed 65.8% of the population. This is in accordance with previous studies reporting almost exactly the same percentage ([@B46]; [@B25]).

Our findings suggest an overall excellent DRR of ANA in both sJIA and AOSD, with an estimated probability of 50% to persist on treatment after 5 years from its initiation. The DRR of ANA does not significantly differ between patients with sJIA and AOSD, implying a similar effectiveness of ANA for both disorders. The drug survival of ANA is not affected by the concomitant use of cDMARDs, highlighting the effectiveness of this specific drug when employed in monotherapy. Other studies reporting long-term efficacy of ANA in sJIA and AOSD patients had shown similar results when comparing adjunct therapy *versus* monotherapy in terms of survival analysis as well as clinical and laboratory response ([@B19], [@B51]). Data reported in this study revealed the similar effectiveness of ANA in sJIA and AOSD, though it remains controversial whether sJIA and AOSD could be considered as an identical disease. However, based on these successful results, many experts contemplate these two entities as a *continuum* of one only disorder affecting different onset ages ([@B10]; [@B32]; [@B15]; [@B22]; [@B23]).

On the other hand, ANA DRR differs significantly between biologic-naïve patients and those already treated with other biotechnologic agents. This observation is in accordance with previous studies recommending ANA administration as first-line biologic agent instead of a rescue therapy in sJIA ([@B30]; [@B12]; [@B49]; [@B35]). In addition, this option might also be applied to AOSD, since the difference between biologic-naïve and biologic-exposed patients still persisted also on a stratified analysis after adjustment for disorder. As also shown by the regression analysis, the biologic line of treatment seems to be a predictive factor for treatment withdrawal with a significantly lower HR for biologic-naïve patients.

Another crucial issue is related to the demand for a prompt introduction of cytokine-blocking therapies to modify the natural disease course by preventing or reducing any structural damage secondary to long-term improperly controlled disease. The significant higher mean treatment delay in patients discontinuing ANA advocates for a timely establishment of biologic therapy. In fact, the therapeutic potential of IL-1 blockade may be fully explored when ANA is used within the "windows of opportunity," an interesting concept firstly developed in 2014 ([@B31]). Indeed, early treatment with IL-1 blockade is presumably able to alter disease progression of both sJIA and AOSD by slowing its evolution and avoiding permanent damages. On the other hand, it is also possible that patients with long-standing disease receiving multiple biologic agents may simply have a more resistant disease. Timely targeted treatment is also important for minimizing inappropriately high cumulative dose of CS and their associated detrimental side effects. Concordant with other authors' observations ([@B20]; [@B19]; [@B8]), in our sample, we found a CS-sparing effect with a significant lower number of patients requiring CS administration on the last follow-up visit. Noteworthy, Nigrovic et al. found that the majority of patients were CS-free by 2 months ([@B30]). Interestingly, a cDMARDs-sparing effect was also observed. The use of IL-1 inhibition has even reduced side effects related to cotreatments while increasing patient's compliance to monotherapy ([@B8]). This drug-sparing effect is essential in the setting of chronic systemic inflammatory disorders in the light of the reduction of side effects, which is of utmost relevance in the pediatric age.

As for AEs, we observed a good overall safety profile for ANA, as only less than one-third of the patients developed AE, which were mild in the vast majority of cases. More in detail, 70% of AEs involved the skin, including injection site reactions in 18 cases. Four cases of death occurred in our cohort of patients with AOSD. However, these cases are considered to be more likely related to the underlying preexisting comorbidities and/or the poor clinical condition of patients with a refractory or complicated AOSD ([@B16]; [@B17]; [@B27]; [@B18]; [@B7]). Additionally, only one patient with AOSD and none of patients with sJIA developed MAS during the follow-up period. In agreement with the latter, a positive experience with ANA in treating pediatric patients with MAS has been also reported ([@B48]). Besides their single center experience showing the resolution of clinical pictures as well as normalization of laboratory parameters, Sönmez et al. performed a systematic literature review and found optimal results in terms of remission and safety profile of ANA in the treatment of MAS. On the other hand, controversial results have been reported with other anti-IL-1 agents ([@B13]; [@B11]). Only one episode of MAS occurred in the long-term extension phase of a randomized study investigating efficacy and safety of rilonacept in sJIA patients ([@B13]). Contrarily, Grom et al. stated that MAS occurs even in sJIA patients properly controlled with biologic therapy ([@B11]). Hence, it is not possible to draw firm conclusions and dedicated prospective randomized studies specifically investigating this dreadful complication are warranted to shed light on this topic.

Potential limitations of our study is its retrospective noncomparative design. Data such as laboratory markers and Pouchot's score were not collected, and therefore we could not assess whether they predicted treatment withdrawal or not. Additionally, given the absence of standardized treatment guidelines, the management of the single patient relied on the personal experience of the local physician.

Conclusions {#s5}
===========

ANA appears a promising drug in both sJIA and AOSD, also when the disease has a long-standing course, displaying a satisfying clinical effectiveness and minimizing long-term requirement of CS. Moreover, ANA exhibits a similar DRR in both sJIA and AOSD and their survival is not affected by the concomitant use of cDMARDs, highlighting its efficacy as monotherapy. A tight monitoring of safety profile is also mandatory, since it can significantly affect ANA DRR. Additionally, DRR is also significantly influenced from the biologic line of treatment, suggesting to employ ANA as a first-line biologic agent. Lastly, our results reveal a significant impact of treatment delay in drug discontinuation, implying that a trend toward an earlier initiation might be crucial to take advantage of the "windows of opportunity" and improve long-term outcomes of patients with both sJIA and AOSD.
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